Ann: Half Yearly Report and Accounts, page-31

A good announcement that got SHL back on my radar. Have always liked the business, i think pathology and health imaging as industries will continue to grow, everytime I go to the Doctors they always refer me some sort of test or image before diagnosis or treatment. Bought it in the Covid dump of 2020 at $25 and naively sold at $35 thinking i made a good profit on it, my profit could have been so much better but i have learnt my lesson now.

Anyways, a strong half of Base business revenue growth and EBITDA growth. Capital structure of the business has really improved thanks to all the cash from Covid testing. $75mil of the Share buyback to go and continued Dividends around 3% yield is nice. I think its a safe bet for the coming years.

We are back into the Pre-Pandemic trend, i started drawing it in 2016 but the trend does go further back. the Downtrend from Covid testing peak has been broken, so it looks like it move up from here. So i see clear skys from here for SHL, the bottom is in IMO. Let me know your thoughts.

DYOR, all IMO